No SGLT2i for Acute Decompensated Heart Failure (ADHF)

Phase-Based Progress Estimates
University of Chicago, Chicago, IL
Acute Decompensated Heart Failure (ADHF)+1 More
SGLT2i - Drug
All Sexes
What conditions do you have?

Study Summary

This trial will study the effects of SGLT2i therapy on patients with acute decompensated heart failure who are admitted to the ICU. This trial will not use SGLT2i to treat Acute Decompensated Heart Failure (ADHF), and all patients will receive an active treatment.

Eligible Conditions

  • Acute Decompensated Heart Failure (ADHF)

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Other trials for Acute Decompensated Heart Failure (ADHF)

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 4 days

4 days
Change in Indirect Fick cardiac index
Change in pulmonary capillary wedge pressure (PCWP)

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Acute Decompensated Heart Failure (ADHF)

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Active Control

40 Total Participants · 2 Treatment Groups

Primary Treatment: No SGLT2i · No Placebo Group · Phase 4

ActiveComparator Group · 1 Intervention: No SGLT2i · Intervention Types: Other
ActiveComparator Group · 1 Intervention: SGLT2i · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4 days
Closest Location: University of Chicago · Chicago, IL
Photo of University of Chicago 1Photo of University of Chicago 2Photo of University of Chicago 3
2004First Recorded Clinical Trial
2 TrialsResearching Acute Decompensated Heart Failure (ADHF)
712 CompletedClinical Trials

Who is running the clinical trial?

University of ChicagoLead Sponsor
909 Previous Clinical Trials
726,907 Total Patients Enrolled
Jonathan Grinstein, MDPrincipal InvestigatorUniversity of Chicago

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are admitted to CCU for decompensated heart failure.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.